# Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin

Study · id `cardio:ct-nct05500937` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05500937](<https://clinicaltrials.gov/study/NCT05500937>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05500937

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT05500937. Randomized; triple masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT05500937, source copy `cardio:ctgov-nct05500937-2022-09-28`, retrieved 2026-10-26)
- Started: 2021-03-01 (actual) (ClinicalTrials.gov record NCT05500937, source copy `cardio:ctgov-nct05500937-2022-09-28`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05500937, source copy `cardio:ctgov-nct05500937-2022-09-28`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05500937, source copy `cardio:ctgov-nct05500937-2022-09-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05500937, source copy `cardio:ctgov-nct05500937-2022-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05500937-2022-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin
- Condition: Diabetes Mellitus
- Intervention (Drug): UDCA
- Lead sponsor: First Affiliated Hospital Xi'an Jiaotong University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital Xi'an Jiaotong University (`cardio:org-first-affiliated-hospital-xi-an-jiaotong-university`)

## Provenance

Content hash: 042d7ef183a68a81faf51d55e043835092ed9eaff1b334ebcbd485f70a398902
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
